A whitening serum containing a whitening composition

Abstract

The present application discloses a whitening essence containing a whitening composition, which comprises the following components in a mass ratio: 0.01%-1% of the whitening composition, 0.1%-3% of a first soothing agent, 0.1%-3% of a second soothing agent, 1%-20% of a humectant, 0.1%-15% of an emollient, 0.1%-4% of an emulsifier, 0.1%-4% of an emulsion stabilizer, 0.1%-3% of a thickening agent, 0.1%-1% of a preservative, and the balance of water, wherein the whitening composition is a mixture of 4-butyl resorcinol, glabridin and licorice chalcone A, the first soothing agent comprises at least one of 4-tert-butylcyclohexanol and citrus fruit extract, and the second soothing agent comprises at least one of bisabolol, ginger extract, asiaticoside, spilanthes extract, sophora extract, glycyrrhiza inflate extract, radix scutellariae extract, calendula extract and panthenol; the essence can inhibit the activity of tyrosinase and reduce the content of melanin from different pathways, has multiple whitening effects, has little skin irritation, and has a good inhibitory effect on black spots induced by UVA+blue light.

Description

Technical Field

[0001] This invention belongs to the technical field of serums, and particularly relates to a whitening serum containing a whitening composition. Background Technology

[0002] In modern society, people live fast-paced, stressful lives, and are often affected by environmental factors, leading to various skin problems that require skincare products for repair. Skin whitening has always been a primary functional demand for skincare products, with fair and radiant skin increasingly sought after by most women. The belief that "fair skin covers a multitude of flaws" further fuels the demand for whitening products. Whitening serums are a commonly used type of skincare product.

[0003] Current serums contain only a single whitening active ingredient. Furthermore, the skin-irritating properties of 4-butylresorcinol limit its dosage in formulations, sometimes causing adverse reactions such as redness, itching, and stinging in test subjects. Industry-standard human whitening tests generally use the common whitening methods in the CFDA standard, including Whitening Method 1 and Whitening Method 2, and the effect of ultraviolet radiation on skin pigmentation. There is limited research on the inhibitory effect of whitening formulas on UVA+blue light-induced pigmentation in Chinese (Type III-IV) skin. Recent studies indicate that small amounts of UVA and blue light cause more persistent pigmentation in darker skin (Type IV-VI). Therefore, the whitening efficacy of serums needs to consider the inhibitory effect of whitening formulas on UVA+blue light-induced pigmentation in Chinese (Type III-IV) skin. Summary of the Invention

[0004] The purpose of this invention is to solve the problems in the background art and to provide a whitening essence containing a whitening composition.

[0005] To achieve the above objectives, the present invention provides a whitening essence containing a whitening composition, wherein the whitening essence comprises the following components in the indicated mass ratios: whitening composition 0.01%–1%, first soothing agent 0.1%–3%, second soothing agent 0.1%–3%, moisturizer 1%–20%, emollient 0.1%–15%, emulsifier 0.1%–4%, emulsion stabilizer 0.1%–4%, thickener 0.1%–3%, and preservative 0.1%–1% The whitening composition comprises 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A in a molar ratio of (2.5-5):1:1, with the first soothing agent comprising at least one of 4-tert-butylcyclohexanol and citrus fruit extract, and the second soothing agent comprising at least one of bisabolol, ginger root extract, asiaticoside, purslane extract, sophora flavescens extract, licorice root extract, scutellaria baicalensis root extract, calendula extract, and panthenol.

[0006] Preferably, the whitening essence further includes 0.01% to 0.5% of a chelating agent, wherein the chelating agent includes at least one selected from ethylenediaminetetraacetic acid, disodium EDTA, tetrasodium EDTA, hydroxyethyl diphosphate, and trisodium EDTA.

[0007] Preferably, the whitening essence further includes a pH adjuster of 0.01% to 0.5%, wherein the pH adjuster includes at least one of triethanolamine, sodium citrate, citric acid, tromethamine, sodium hydroxide, potassium hydroxide, arginine, and lactic acid.

[0008] Preferably, the whitening essence also includes 0% to 0.5% (daily use) fragrance.

[0009] Preferably, the moisturizer includes at least one of 1,3-butanediol, propylene glycol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, methyl propylene glycol, sodium hyaluronate, sodium hyaluronate derivatives, β-glucan, glyceryl polyether-26, sorbitol, methyl glucetol polyether-20, trehalose, betaine, xylitol glucoside, xylitol, glyceryl glucoside, sodium PCA, acetylglucosamine, and glycerin.

[0010] Preferably, the emollient comprises at least one of the following: dimethicone, triglycerides (ethylhexanoate), squalane, cetyl ethylhexanoate, caprylic / capric triglyceride, polyglycerol-2 triisostearate, hydrogenated polyisobutylene, isononyl isononanoate, isotretinoate, pentaerythritol tetracaprylate, hydrogenated polydecene, isododecane, isohexadecane, pentaerythritol tetra(ethylacetic acid), neopentyl glycol didecanoate, shea butter, beeswax, and jojoba esters.

[0011] Preferably, the emulsifier comprises at least one of sodium stearoyl glutamate, phytosterol / octyldodecyl lauroyl glutamate, polyglycerol-3-methyl glucoside distearate, polyglycerol-10 stearate, polyglycerol-3 beeswax ester, hydrogenated lecithin, polyglycerol-6 distearate, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, sorbitan sesquioleate, sorbitan isostearate, behenyl alcohol polyether-10, C12-20 alkyl glucoside, polysorbate 80, polysorbate-60, and sorbitan oleate, and the emulsifying stabilizer comprises at least one of cetyl alcohol, C14-22 alcohol, behenyl alcohol, and stearyl alcohol.

[0012] Preferably, the preservative includes at least one of p-hydroxyacetophenone, phenoxyethanol, ethylhexylglycerin, caprylyl glycol, o-cymene-5-ol, and capryloyl hydroxamic acid, and the thickener includes at least one of carbomer, xanthan gum, dehydroxanthan gum, acrylate / C10-30 alkanol acrylate crosspolymer, cassava starch, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, polyacrylate crosspolymer-6, sodium polyacryloyldimethyl taurate, polydimethylsiloxane / vinyl polydimethylsiloxane crosspolymer, ammonium acryloyldimethyl taurate / behenol polyether-25 methacrylate crosspolymer, sodium polyacrylate grafted starch, and ammonium acryloyldimethyl taurate / VP copolymer.

[0013] Preferably, the whitening composition is a mixture of 4-butylresorcinol, glycyrrhizin and glycyrrhizin chalcone A in a molar ratio of 5:1:1.

[0014] Preferably, the 4-butylresorcinol accounts for 0.05% to 0.3% of the whitening essence by mass, the glycyrrhizin accounts for 0.02% to 0.12% of the whitening essence by mass, and the glycyrrhizin chalcone A accounts for 0.02% to 0.12% of the whitening essence by mass.

[0015] The efficacy of each ingredient in this whitening essence: 4-Butylresorcinol inhibits melanin production, as well as the activity of tyrosinase and TRP-1. It inhibits melanin production by directly inhibiting the synthesis of tyrosinase and the activity of B16 melanoma cells, without causing any cytotoxicity; Glycyrrhizin has a strong tyrosinase inhibitory effect, reducing melanin production by decreasing the secretion of MSH (melanocyte-stimulating hormone). In addition, its biological activities include antioxidant, anti-inflammatory, neuroprotective, anti-atherosclerotic, and energy metabolism regulation effects, as well as anti-tumor and anti-nephritis effects; Glycyrrhizin chalcone A is a flavonoid compound extracted from licorice root. It has antibacterial, anti-inflammatory, anti-allergic, and anti-photoaging pharmacological effects, and can inhibit tyrosinase activity, reducing melanin production by lowering the level of PGE2 (inflammatory factor).

[0016] The first soothing agent in this whitening serum inhibits the capsaicin receptor TRPV1 pathway to reduce skin irritation such as burning or stinging sensations. The second soothing agent inhibits inflammatory factor pathways to reduce inflammatory reactions such as redness and swelling after skin irritation.

[0017] A schematic diagram illustrating part of the mechanism of action of this whitening composition is described in the reference Christina Wasmeier, Alistair N Hume, Giulia Bolasco, Miguel C Seabra. Melanosomes at a glance. J Cell Sci. 2008 Dec 15; 121(Pt 24):3995-9.

[0018] The beneficial effects of this invention are as follows: This invention adds a whitening composition formed by mixing 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A in a specific ratio to a whitening essence. The three active ingredients work synergistically to inhibit tyrosinase activity and reduce melanin content to the greatest extent through different pathways, achieving multiple whitening effects. Glycyrrhizin and glycyrrhizin chalcone A can reduce the irritation of 4-butylresorcinol. The first soothing agent added to the essence can effectively inhibit the capsaicin receptor TRPV1 pathway, and the second soothing agent can effectively inhibit the inflammatory factor pathway, effectively reducing the irritation of the essence to the skin and avoiding adverse skin reactions such as redness, itching, and stinging during use. This whitening essence has a good inhibitory effect on dark spots induced by UVA+ blue light in Chinese test subjects.

[0019] The features and advantages of the present invention will be described in detail through embodiments and in conjunction with the accompanying drawings. Attached Figure Description

[0020] Figure 1 This is a schematic diagram illustrating the mechanism of action of the whitening composition according to an embodiment of the present invention.

[0021] Figure 2 This is a schematic diagram illustrating the changes in MI values ​​of subjects before and after using different samples according to an embodiment of the present invention.

[0022] Figure 3 This is a schematic diagram illustrating the changes in L values ​​of subjects before and after using different samples in an embodiment of the present invention.

[0023] Figure 4 This is a schematic diagram illustrating the changes in visual scores of subjects before and after using different samples according to an embodiment of the present invention. Detailed Implementation

[0024] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, and not all embodiments.

[0025] Example 1

[0026] This embodiment provides a whitening essence containing a whitening composition, which comprises the following components in the indicated weight ratios: 0.05% 4-butylresorcinol, 0.02% glycyrrhizin, 0.02% glycyrrhizin chalcone A, 0.05% disodium EDTA, 0.03% citric acid, 6% glycerin, 3% butylene glycol, 0.03% sodium hyaluronate, 5% niacinamide, 0.2% sodium stearoyl glutamate, 0.5% p-hydroxyacetophenone, 0.6% 1,2-hexanediol, 0.7% sorbitan sesquioleate, 3% caprylic / capric triglyceride, 2% pentaerythritol tetra(ethylhexanoate), 0.5% tocopheryl acetate, and 4% polydimethylsiloxane. The composition comprises 60.5% polyacrylate crosspolymer, 0.8% hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, 0.5% isohexadecane, 0.1% polysorbate-60, 0.05% sorbitan isostearate, 0.1% Sophora flavescens root extract, 0.1% Scutellaria baicalensis root extract, 0.5% citrus fruit extract, and 71.65% water. 4-Butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A are mixed to form a whitening composition.

[0027] Example 2

[0028] This embodiment provides a whitening essence containing a whitening composition, which comprises the following components in the indicated weight ratios: 0.3% 4-butylresorcinol, 0.12% glycyrrhizin, 0.12% glycyrrhizin chalcone A, 0.05% disodium EDTA, 0.03% citric acid, 6% glycerin, 3% butylene glycol, 0.05% xanthan gum, 4% niacinamide, 0.2% sodium stearoyl glutamate, 0.5% p-hydroxyacetophenone, 0.6% 1,2-hexanediol, 2% betaine, 1% squalane, 0.7% sorbitan sesquioleate, 3% caprylic / capric triglyceride, 2% hydrogenated polydecene, 0.2% tocopheryl acetate, and 4% polydimethylsiloxane. The composition comprises: 60.5% polyacrylate crosspolymer, 0.8% hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, 0.5% isohexadecane, 0.1% polysorbate-60, 0.05% sorbitan isostearate, 0.2% Sophora flavescens root extract, 0.3% Scutellaria baicalensis root extract, 0.5% citrus fruit extract, and 69.18% water. 4-Butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A are mixed to form a whitening composition.

[0029] Example 3

[0030] This embodiment provides a whitening essence containing a whitening composition, which comprises the following components in the indicated weight ratios: 0.4% 4-butylresorcinol, 0.16% glycyrrhizin, 0.16% glycyrrhizin chalcone A, 0.05% disodium EDTA, 0.03% citric acid, 6% glycerin, 3% butylene glycol, 0.03% xanthan gum, 4% niacinamide, 0.2% sodium stearoyl glutamate, 0.5% p-hydroxyacetophenone, 0.6% 1,2-hexanediol, 2% trehalose, 0.7% sorbitan sesquioleate, 3% caprylic / capric triglyceride, 2% hydrogenated polydecene, 0.2% tocopheryl acetate, 4% polydimethylsiloxane, and 4% acryloyl dimethyl ether. The whitening composition comprises 0.8% ammonium methyl taurate / VP copolymer, 0.8% hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, 0.5% isohexadecane, 0.1% polysorbate-60, 0.05% sorbitan isostearate, 0.2% Sophora flavescens root extract, 0.3% Scutellaria baicalensis root extract, 0.5% citrus fruit extract, and 69.72% water. 4-Butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A are mixed to form the whitening composition.

[0031] I. Skin irritation test of the essence of this invention

[0032] Thirty-three subjects aged 22-40 years with sensitive skin (no skin diseases or damage) were selected, including 5 males and 28 females. A closed patch test was conducted according to the testing methods in the "Cosmetic Safety Technical Specifications" (2015 edition). The test product was the essence of this invention, and a blank control was set up. Skin reactions of each subject were observed at 0.5h, 24h, and 48h after the removal of the test product patch. The test results showed that the skin reaction score of all 33 sensitive skin subjects was 0 at 0.5h, 24h, and 48h after the removal of the test product patch, indicating that no adverse skin reactions occurred after using this essence.

[0033] II. Test on the effect of the essence of this invention on inhibiting dark spots on skin under UVA+ blue light conditions

[0034] One hundred Chinese subjects aged 22-40 with skin type III-IV (no skin diseases or lesions) were selected and divided into two groups (the age distribution and male-to-female ratio of the two groups were basically the same). One group was the experimental group and the other group was the control group.

[0035] The minimum dose at which skin darkening occurred was recorded as the MPPD by irradiating the subject's skin with UVA and BL, respectively. UVA Value and MPPD BL The value determines the MPPD.

[0036] Melasma induction test: 1) Select the back of the subject as the test site, clean the test site of each subject with a wet tissue, and let the subject sit quietly for 10 minutes to adapt to the environment; 2) Administer the test sample at a concentration of (2.00±0.05) mg / cm². 2 Apply the prescribed amount to the pre-drawn test area and wait 15 minutes for absorption. The test sample applied to the experimental group was the essence of this invention, while the test sample applied to the control group was a commercially available essence. 3) Refer to MPPD UVA and MPPD BL Irradiation was performed using a certain dose of UVA and BL as the light source; 4) After each day's irradiation, the test substance was applied as described in step 2); 5) Steps 1-4 were repeated for five consecutive days. During the test, the skin color of each melanized test area of ​​the subject was visually assessed and measured using instruments daily. The specific test procedure is as follows:

[0037] Skin color measurement: The L value and MI value of the skin were measured in each darkened area using the DSM II ColorMeter skin color meter.

[0038] Visual assessment of skin color: Dermatologists or experts use a color chart of skin tones from light to dark to assess the skin color of each darkening test area and record the scores in a timely manner.

[0039] Skin color measurement results and skin color visual assessment results, such as Figures 2 to 4 As shown.

[0040] Depend on Figure 2 It can be seen that the skin MI value of the whitening essence of this invention was lower in subjects after using it on days 2-5 than that of subjects after using the control sample, and the difference was more significant during days 3-5, indicating that the whitening essence can significantly inhibit melanin increase starting from day 2. It should be noted that the MI value represents the skin melanin content; the lower the value, the less melanin.

[0041] Depend on Figure 3 It can be seen that the skin L-value of the subjects using the whitening essence of this invention was higher after D2-D4 than that of the subjects using the control sample, and the difference was more significant during D2-D4. A significant directional difference was observed after D5, indicating that this whitening essence can significantly inhibit the decrease in skin brightness. It should be noted that the L-value represents skin brightness; the higher the value, the brighter the skin.

[0042] Depend on Figure 4 As can be seen, compared with the control sample, the visual score of the whitening essence of this invention was lower in subjects after using the control sample from D2 to D4, and the difference between the two gradually increased, indicating that the whitening essence of this invention has the tendency to inhibit the darkening of skin tone. It should be noted that the lower the visual score, the lighter the color.

[0043] III. Tests on the whitening efficacy of different whitening drugs:

[0044] Melanin (MNT1) cells were cultured in DMEM medium with 20% serum and antibiotics in culture dishes placed in a cell culture incubator (37℃, 5% CO2 environment). The MNT1 cells were divided into 11 equal groups and cultured under the same conditions. When the cell density reached 60%, equal amounts of different whitening ingredients were added to each group (the whitening ingredients and concentrations added to each group are shown in Table 1 below). After 48 hours of culture, each group of cells was digested with trypsin, centrifuged at 800 rpm for 5 minutes, and 200 μL of 20 mM Tris-HCl (pH 10.5) was added to each group. 7.0) Resuspended cells in 0.1% Triton-X100 solution and lysed on ice for 30 min. Each lysate was divided into two portions. The first portion was added with an equal volume of 1 mg / mL L-DOPA and incubated at 37℃ for 4 h. Absorbance was measured at 490 nm to detect tyrosinase activity. The second portion was added with RIPA lysate and centrifuged at 12000 rpm for 10 min at 4℃. The supernatant was used for BCA assay to determine total protein concentration. The precipitate was resuspended in 1M NaOH and reacted at 50℃ for 1 h. Absorbance was measured at 490 nm to determine melanin content. During the experiment, tyrosinase activity and melanin content were corrected for protein concentration. The blank control group cells were treated with either no whitening ingredients or deionized water. Whitening ingredients were dissolved in DMSO before addition. All whitening ingredients listed in Table 1 were purchased from the market. The specific test results for tyrosinase activity and melanin content in each group of cells are shown in Table 1 below.

[0045] Table 1. Test results of tyrosinase activity and melanin content in MNT1 cells treated with different whitening ingredients.

[0046]

[0047]

[0048] Table 1 shows the results of tyrosinase activity tests in each group of cells: Compared with the blank control group, the addition of 377, glycyrrhizin, glycyrrhizin chalcone A, and 4-butylresorcinol significantly reduced tyrosinase activity. The results of the tyrosinase activity reduction test are as follows: 377 > glycyrrhizin chalcone A > glycyrrhizin > 4-butylresorcinol. Under the same concentration conditions, 4-butylresorcinol was not very effective in inhibiting tyrosinase activity. When 10 μM 4-butylresorcinol was used in combination with 10 μM glycyrrhizin chalcone A, it significantly reduced tyrosinase activity compared with the blank control group, but the inhibitory effect was still not as good as that of 377. Adding 10 μM glycyrrhizin further showed little difference in inhibitory effect. When the concentration of 4-butylresorcinol reached 50 μM, its inhibitory efficiency increased significantly when combined with 10 μM glycyrrhizin and 10 μM glycyrrhizin chalcone A, and was superior to all control groups. The whitening composition formulated according to the present invention has an inhibitory efficiency of approximately 1.5 times higher on tyrosinase compared to the same concentration of 4-butylresorcinol.

[0049] The above results indicate that the synergistic use of 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A, compared to single or dual whitening ingredients, better inhibits tyrosinase activity. Furthermore, the combination of 50 μM 4-butylresorcinol + 10 μM glycyrrhizin + 10 μM glycyrrhizin chalcone A resulted in the most significant inhibition of tyrosinase activity. Table 1 shows the melanin content test results for each group of cells as follows: Compared to the blank control, the addition of 377, glycyrrhizin, glycyrrhizin chalcone A, and 4-butylresorcinol significantly reduced the melanin content of MNT1 cells. The results of the melanin reduction effect test are as follows: glycyrrhizin > 377 > glycyrrhizin chalcone A > 4-butylresorcinol; 4-butylresorcinol was not very effective in reducing melanin in MNT1 melanocytes. When 10 μM 4-butylresorcinol was used in combination with 10 μM glycyrrhizin A, it significantly reduced the melanin content of MNT 1 cells compared to the blank control group, but the effect was still not as good as that of 377. Adding 10 μM glycyrrhizin to this combination slightly improved the reduction of melanin content in MNT 1 cells. The composition (i.e., 4-butylresorcinol + 10 μM glycyrrhizin + 10 μM glycyrrhizin) showed a decreasing trend in melanin content in MNT 1 cells with increasing 4-butylresorcinol concentration. The whitening composition formulated according to this invention showed an approximately 1.24-fold increase in the inhibitory efficiency of melanin production compared to the same concentration of 4-butylresorcinol.

[0050] The above results indicate that the synergistic use of 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A significantly reduces MNT1 melanocytes compared to single or dual whitening ingredients. Furthermore, the effect of reducing melanin content is most pronounced when the concentration of 4-butylresorcinol reaches 50 μM, surpassing all control groups. Therefore, the combined use of 50 μM 4-butylresorcinol, 10 μM glycyrrhizin, and 10 μM glycyrrhizin chalcone A yields the most significant effect in reducing melanin content.

[0051] The above experiments show that different ratios of 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A in the whitening composition have a certain impact on the inhibitory effect on tyrosinase activity and melanin content in cells. When the whitening composition is compounded, an excessively high or low proportion of 4-butylresorcinol prevents the optimal inhibition of tyrosinase activity and reduction of melanin content. The whitening composition of this invention, by mixing 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A in a specific ratio, allows the three whitening active ingredients to work synergistically, inhibiting tyrosinase activity through different pathways, maximizing the reduction of tyrosinase activity and melanin content in cells, achieving multiple whitening effects. Glycyrrhizin and glycyrrhizin chalcone A can reduce the irritation of 4-butylresorcinol, making the whitening composition gentler to use and suitable as a raw material for whitening skincare products. The concentration ratio of the three whitening active ingredients is also important.

[0052] IV. Regarding the whitening efficacy test of the whitening composition:

[0053] Melanin (MNT1) cells were cultured in DMEM medium with 20% serum and antibiotics in culture dishes placed in a cell culture incubator (37℃, 5% CO2 environment). The MNT1 cells were divided into 5 equal groups and cultured under the same conditions. When the cell density reached 60%, equal amounts of different whitening ingredients were added to each group (the whitening ingredients and concentrations added to each group are shown in Table 2 below). After 48 hours of culture, each group of cells was digested with trypsin, centrifuged at 800 rpm for 5 minutes, and 200 μL of 20 mM Tris-HCl (pH 10.5) was added to each group. 7.0) Resuspend cells in 0.1% Triton-X100 solution and lyse on ice for 30 min. Divide each lysate into two portions. Add an equal volume of 1 mg / mL L-DOPA to the first portion and incubate at 37℃ for 4 h. Measure absorbance at 490 nm to detect tyrosinase activity. Add RIPA lysate to the second portion and centrifuge at 12000 rpm for 10 min at 4℃. Use the supernatant for BCA assay to determine total protein concentration. Resuspend the precipitate in 1M NaOH and react at 50℃ for 1 h. Measure absorbance at 490 nm to determine melanin content. During the experiment, tyrosinase activity and melanin content were corrected for protein concentration. The blank control group cells were treated with either no whitening ingredients or deionized water. Whitening ingredients were dissolved in DMSO before addition. All whitening ingredients listed in Table 2 were purchased from the market. The specific test results of tyrosinase activity and melanin content for each group of cells are shown in Table 2 below.

[0054] Table 2. Test results of tyrosinase activity and melanin content in MNT1 cells treated with different whitening ingredients.

[0055]

[0056] As shown in Table 2, the whitening composition consisting of 100 μM 4-butylresorcinol, 10 μM glycyrrhizin, and 10 μM glycyrrhizin A does not show a significant synergistic effect in inhibiting tyrosinase activity and melanin production compared to single whitening ingredients such as 100 μM 4-butylresorcinol, 10 μM glycyrrhizin, or glycyrrhizin A.

[0057] The above embodiments are illustrative of the present invention and are not intended to limit the present invention. Any simple modifications to the present invention are within the scope of protection of the present invention.

Claims

1. A whitening essence containing a whitening composition, characterized in that, The whitening essence comprises the following components in the indicated mass ratios: 0.01%–1% whitening composition, 0.1%–3% first soothing agent, 0.1%–3% second soothing agent, 1%–20% moisturizer, 0.1%–15% emulsifier, 0.1%–4% emulsion stabilizer, 0.1%–3% thickener, 0.1%–1% preservative, and the balance being water. The whitening composition is a mixture of 4-butylresorcinol, glycyrrhizin, and glycyrrhizin chalcone A in a molar ratio of (2.5–5):1:

1. The first soothing agent includes at least one of 4-tert-butylcyclohexanol and citrus fruit extract; the second soothing agent includes at least one of bisabolol, ginger root extract, asiaticoside, purslane extract, sophora flavescens extract, scutellaria baicalensis root extract, calendula extract, and panthenol; the 4-butylresorcinol accounts for 0.05% to 0.3% of the whitening essence by mass; the glycyrrhizin accounts for 0.02% to 0.12% of the whitening essence by mass; and the glycyrrhizin chalcone A accounts for 0.02% to 0.12% of the whitening essence by mass.

2. The whitening essence containing the whitening composition as described in claim 1, characterized in that: The whitening essence also includes 0.01% to 0.5% of a chelating agent, which includes at least one of ethylenediaminetetraacetic acid, disodium EDTA, tetrasodium EDTA, hydroxyethyl diphosphate, and trisodium EDTA.

3. The whitening essence containing a whitening composition as described in claim 1 or 2, characterized in that: The whitening essence also includes a pH adjuster of 0.01% to 0.5%, wherein the pH adjuster includes at least one of triethanolamine, sodium citrate, citric acid, tromethamine, sodium hydroxide, potassium hydroxide, arginine, and lactic acid.

4. The whitening essence containing a whitening composition as described in claim 1, characterized in that: The whitening essence also includes 0% to 0.5% fragrance.

5. The whitening essence containing a whitening composition as described in claim 1, characterized in that: The moisturizer includes at least one of the following: 1,3-butanediol, propylene glycol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, methyl propylene glycol, sodium hyaluronate, sodium hyaluronate derivatives, β-glucan, glyceryl polyether-26, sorbitol, methyl glucetol polyether-20, trehalose, betaine, xylitol glucoside, xylitol, glyceryl glucoside, sodium PCA, acetylglucosamine, and glycerin.

6. The whitening essence containing the whitening composition as described in claim 1, characterized in that: The emollients include at least one of the following: dimethicone, triglycerides (ethylhexanoate), squalane, cetyl ethylhexanoate, caprylic / capric triglyceride, polyglycerol-2 triisostearate, hydrogenated polyisobutylene, isononyl isononanoate, isotretinoate, pentaerythritol tetracaprylate, hydrogenated polydecene, isododecane, isohexadecane, pentaerythritol tetra(ethylacetic acid), neopentyl glycol didecanoate, shea butter, beeswax, and jojoba esters.

7. The whitening essence containing a whitening composition as described in claim 1, characterized in that: The emulsifier includes at least one of sodium stearoyl glutamate, phytosterol / octyldodecyl lauroyl glutamate, polyglycerol-3-methyl glucoside distearate, polyglycerol-10 stearate, polyglycerol-3 beeswax ester, hydrogenated lecithin, polyglycerol-6 distearate, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer, sorbitan sesquioleate, sorbitan isostearate, behenyl alcohol polyether-10, C12-20 alkyl glucoside, polysorbate 80, polysorbate-60, and sorbitan oleate; and the emulsifying stabilizer includes at least one of cetyl alcohol, C14-22 alcohol, behenyl alcohol, and stearyl alcohol.

8. The whitening essence containing the whitening composition as described in claim 1, characterized in that: The preservative includes at least one of p-hydroxyacetophenone, phenoxyethanol, ethylhexylglycerin, octyl glycol o-cymene-5-ol, and octanoyl hydroxamic acid; the thickener includes at least one of carbomer, xanthan gum, dehydroxanthan gum, acrylate / C10-30 alkanol acrylate crosspolymer, tapioca starch, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, polyacrylate crosspolymer-6, sodium polyacryloyldimethyl taurate, polydimethylsiloxane / vinyl polydimethylsiloxane crosspolymer, ammonium acryloyldimethyl taurate / behenol polyether-25 methacrylate crosspolymer, sodium polyacrylate grafted starch, and ammonium acryloyldimethyl taurate / VP copolymer.

9. The whitening essence containing the whitening composition as described in claim 1, characterized in that: The whitening composition is a mixture of 4-butylresorcinol, glycyrrhizin and glycyrrhizin chalcone A in a molar ratio of 5:1:1.

Images